Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Christoph Male(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Philip Maes(Noah's Ark Children's Hospital for Wales), Kerry Hege(Indiana University Health), Krisztián Kállay, Cynthia Gauger, Angelo Claudio Molinari, Ida Martinelli(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gernot Grangl, Paola Saracco(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paolo Simioni(University of Padua), Marjolein Peters(Emma Kinderziekenhuis), Madhurima Majumder(Bayer (United States)), Susanne Holzhauer(Charité - Universitätsmedizin Berlin), Dagmar Kubitza(Bayer (Germany)), An Van Damme(Cliniques Universitaires Saint-Luc), Gili Kenet(Sheba Medical Center), Riten Kumar(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Marcela Torres(McMaster University), Amparo Santamaría(Hospital de Sant Pau), Scott D. Berkowitz(Bayer (United States)), Damien Bonnet(World Rugby), Werner Streif(Innsbruck Medical University), Paul Monagle(Murdoch Children's Research Institute), Hélène L. Hooimeijer(University Medical Center Groningen), Anthony K.C. Chan(McMaster Children's Hospital), Juan José Chain, Pascal Amédro(Université de Bordeaux), Donald L. Yee(Baylor College of Medicine), Jeremy Robertson, Elizabeth Chalmers(Royal Hospital for Children), Mark Crowther(Population Health Research Institute), O. Lvova(Ural Federal University), Tina Biss(Royal Victoria Infirmary), Ákos F. Pap(Bayer (Germany)), M. Patricia Massicotte(Stollery Children's Hospital), Kirstin Thelen(Bayer (Germany)), Ildar Nurmeev(Kazan State Medical University), Katharina Thom(Medical University of Vienna), Klaus Schmitt(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Jan Beyer‐Westendorf(Population Health Research Institute), William T. Smith(Bayer (United States)), Philip Connor(University Hospital of Wales), Jürgen F. Heubach(Bayer (Germany)), Anthonie W.A. Lensing(Bayer (Germany)), Martin H. Prins(Maastricht University), Rudolf Schwarz(Universität Hamburg), Ulrike Nowak- Gottl, Rukhmi Bhat(Northwestern University), Joseph S. Palumbo(Cincinnati Children's Hospital Medical Center), Guy Young(Children's Hospital of Los Angeles)
Cited by 329
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
|Blood|2002|1.9k
Evidence-Based Management of Anticoagulant Therapy
|CHEST Journal|2012|1.3k
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
|New England Journal of Medicine|2015|1k